AUA 2016: Impact of Abiraterone Acetate in Prostate Specific AntiGEN Trial Update: Effect of abiraterone acetate and low dose prednisone on prostate-specific antigen and radiographic disease progression in patients with nmCRPC
San Diego, California (UroToday.com): Charles Ryan, MD discussed data on the effect of abiraterone acetate and low dose prednisone on prostate-specific antigen and radiographic disease progression in patients with non-metastatic castration-resistant prostate cancer. Abiraterone acetate (AA) in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The authors report updated results of the IMAAGEN study evaluating the efficacy of abiraterone in decreasing PSA levels in patients with non-metastatic CRPC and a rising PSA. The study enrolled 131 high risk non-metastatic prostate cancer patients with PSA higher than 10 ng/mL and PSA doubling time of fewer than 10 months. The patients received daily abiraterone for 28 days cycles. The study examined the time to PSA progression, time to radiographic progressive disease, and safety of the treatment. 47.3% of the enrolled patients remained on the treatment and the median time of treatment was 17.9 months. Median time to PSA progression was 28.7 months. 21 patients demonstrated radiographic progression. 95.4% of patients experienced an adverse event.
35.9% of patients experienced a serious adverse event of grade 3 or higher. Four patients had AEs resulting in death (coronary artery disease, myocardial infarction, acute respiratory failure, and pneumonia). The authors conclude that the safety profile of abiraterone in the non-metastatic cohort is similar to previously published data in the metastatic setting.
Presented By: Charles Ryan, MD
Written By: Miki Haifler MD. Fox Chase Cancer Center, Philadelphia, PA. at the 2016 AUA Annual Meeting - May 6 - 10, 2016 – San Diego, California, USA